HBW Insight is part of Pharma Intelligence UK Limited

This site is operated by Pharma Intelligence UK Limited, a company registered in England and Wales with company number 13787459 whose registered office is 5 Howick Place, London SW1P 1WG. The Pharma Intelligence group is owned by Caerus Topco S.à r.l. and all copyright resides with the group.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction

L’Oreal Teams With Femtech Pioneer To Improve Menstrual Cycle-Skin Health Understanding

Executive Summary

“Through this partnership we want to pioneer scientific innovation,” says L’Oreal’s Barbara Lavernos, president of research, innovation and technologies, who was named deputy CEO in October 2020.

You may also be interested in...



L’Oreal Q2 Lifted By Consumer Biz Revival And ‘Probably Our Greatest Makeup Launch Ever’

Maybelline Lash Sensational Sky High Mascara, along with NYX Shine Loud Lip Color and L’Oreal Paris Infallible Fresh Wear 24HR Foundation, were among innovations gobbled up by makeup-hungry consumers in the second quarter, which helped fuel 23% growth in North America in L'Oreal's fiscal 2021 first half.

L’Oreal Names CEO To Follow Agon; ELC And Coty Appoint Digital Leadership; Executive News In Brief

Deputy CEO Nicolas Hieronimus will take L’Oreal’s helm beginning in May 2021, with Jean-Paul Agon continuing as chairman, the firm announced on 14 October. The Estee Lauder Companies hires PepsiCo’s Gibu Thomas to lead its online business, and Coty appoints its first chief digital officer.

Unilever’s Dove Recommits To ‘Real Women’ Against Rising AI Threat

Unilever PLC’s Dove and Baby Dove brands continue tackling prominent social causes with a vow to be responsible about representing women realistically in advertising in the age of AI and a renewed commitment to closing the Black maternal care gap.

Topics

Latest Headlines
See All
UsernamePublicRestriction

Register

RS151645

Ask The Analyst

Ask the Analyst is free for subscribers.  Submit your question and one of our analysts will be in touch.

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel